


REMARKS

Further to the Amendment under 37 C.F.R. § 1.116 filed October 11, 2007, the “genotypically or phenotypically confirming the diagnosis or the determination of the presence or absence or risk or assessment of the level of risk” in claim 1 is supported at least at page 2 of the specification and is inherent in the disclosure.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



William J. Simmons, Ph.D.
Registration No. 59,887

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: November 13, 2007